Men who use AndroGel and other prescription testosterone treatments may be in danger of experiencing a potentially deadly type of blood clot called deep vein thrombosis. In June 2014, the U.S. Food & Drug Administration (FDA) ordered all low-T manufacturers to add new warnings to their product labels regarding a potential risk for venous blood clots, including deep vein thrombosis.
Thousands of men have filed testosterone lawsuits in order to obtain compensation for heart attacks, stroke, blood clots, and other cardiovascular complications allegedly associated with the use of low-T therapy. If you would like to learn more about the compensation that could be available to men who allegedly suffered a testosterone-related deep vein thrombosis, please call (888) 994-5118 to arrange for a free, no-obligation case review with the legal team at Bernstein Liebhard LLP.
Prescription testosterone treatments currently approved for use by the FDA including:
Low-T therapy is approved for the treatment of hypogonadism (low testosterone levels) that is related to another underlying medical condition. Since 2009, the number of patients receiving a prescription for low-T therapy has grown from 1.3 million patients in 2009 to 2.3 million patients in 2013. Thousands of testosterone lawsuit plaintiffs attribute this explosive growth to allegedly deceptive marketing tactics that characterized the drugs as appropriate remedies weight gain, fatigue, low libido, and other problems associated with age-related hypogonadism. However, the drugs have never been approved for this indication. Read More
Testosterone treatments are associated with a condition that causes the blood to thicken called polycythemia. This occurrence is linked to the development of venous blood clots, including deep vein thrombosis. As such, the labels for this class of medication have long included warning about the potential for blood clots associated with polycythemia
in June 2014, the FDA required manufacturers to include a general warning in the drug labeling of all approved testosterone products about the risk of venous thromboembolism, venous blood clots that include deep vein thrombosis and pulmonary embolism. The label change was prompted by post-marketing reports of venous blood clots that had occurred in the absence of polycythemia. Read More
A deep vein thrombosis, or DVT, is a blood clot in one or more of the deep veins in the body, usually in the legs, arms or pelvis. Symptoms of the condition include:
A deep vein thrombosis can break loose, travel through the bloodstream and lodge in the lungs, where it becomes a life-threatening pulmonary embolism.
There is still time for the alleged victims of testosterone-related deep vein thrombosis to file their own lawsuits against the manufacturers of low-T therapies. To learn more about this growing litigation, please contact our attorneys today, by calling (888) 994-5118.
Get the latest news and litigation updates about this case by following us on Facebook. Click the "Like" button below.